Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial

    July 2021 in “ Frontiers in Medicine ”
    J. Philip McCoy, Andy Goren, Flavio Cadegiani … Carlos Gustavo Wambier
    Studysummary In this study, proxalutamide significantly reduced the 30-day hospitalization rate by 91% compared to placebo in men with COVID-19 treated in outpatient settings.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on frontiersin.org →
    Discuss this study in the Community →

    Research cited in this study 13

    1. Finasteride in Hospitalized Adult Males with COVID-19: A Risk Factor for Severity or an Adjunct Treatment - A Randomized Controlled Clinical Trial Medical journal of the Islamic Republic of Iran · 2021
    2. Response to Effectiveness of Dutasteride in a Large Series of Patients with Frontal Fibrosing Alopecia in Real Clinical Practice 2021
    3. Alopecia and Severity of COVID-19: A Cross-Sectional Study in Peru Le infezioni in medicina · 2021
    4. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial Cureus · 2021
    5. Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users BMJ case reports · 2021
    6. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial Cureus · 2021
    7. Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men Journal of The European Academy of Dermatology and Venereology · 2021
    8. Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men Cell Stem Cell · 2020
    9. 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia Journal of The European Academy of Dermatology and Venereology · 2020
    10. Alopecia and Grey Hair Are Associated with COVID-19 Severity Experimental Dermatology · 2020
    11. Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign Journal of The American Academy of Dermatology · 2020
    12. Male Balding Is a Major Risk Factor for Severe COVID-19 Journal of The American Academy of Dermatology · 2020
    13. Brazilian Blood Donation Eligibility Criteria for Dermatologic Patients Anais Brasileiros de Dermatologia · 2012